Summary | |
---|---|
Symbol | HLA-E |
Name | major histocompatibility complex, class I, E |
Aliases | EA1.2; EA2.1; HLA-6.2; MHC; QA1; HLA class I histocompatibility antigen, E alpha chain; MHC HLA-E alpha-1; M ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Membrane; Single-pass type I membrane protein. |
Domain |
PF07654 Immunoglobulin C1-set domain PF00129 Class I Histocompatibility antigen PF06623 MHC_I C-terminus |
Function |
Preferably binds to a peptide derived from the signal sequence of most HLA-A, -B, -C and -G molecules. |
Biological Process |
GO:0001819 positive regulation of cytokine production GO:0001906 cell killing GO:0001909 leukocyte mediated cytotoxicity GO:0001910 regulation of leukocyte mediated cytotoxicity GO:0001911 negative regulation of leukocyte mediated cytotoxicity GO:0001912 positive regulation of leukocyte mediated cytotoxicity GO:0001913 T cell mediated cytotoxicity GO:0001914 regulation of T cell mediated cytotoxicity GO:0001916 positive regulation of T cell mediated cytotoxicity GO:0002228 natural killer cell mediated immunity GO:0002250 adaptive immune response GO:0002377 immunoglobulin production GO:0002428 antigen processing and presentation of peptide antigen via MHC class Ib GO:0002440 production of molecular mediator of immune response GO:0002443 leukocyte mediated immunity GO:0002449 lymphocyte mediated immunity GO:0002456 T cell mediated immunity GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002474 antigen processing and presentation of peptide antigen via MHC class I GO:0002475 antigen processing and presentation via MHC class Ib GO:0002476 antigen processing and presentation of endogenous peptide antigen via MHC class Ib GO:0002478 antigen processing and presentation of exogenous peptide antigen GO:0002479 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002480 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002483 antigen processing and presentation of endogenous peptide antigen GO:0002637 regulation of immunoglobulin production GO:0002639 positive regulation of immunoglobulin production GO:0002683 negative regulation of immune system process GO:0002694 regulation of leukocyte activation GO:0002696 positive regulation of leukocyte activation GO:0002697 regulation of immune effector process GO:0002698 negative regulation of immune effector process GO:0002699 positive regulation of immune effector process GO:0002700 regulation of production of molecular mediator of immune response GO:0002702 positive regulation of production of molecular mediator of immune response GO:0002703 regulation of leukocyte mediated immunity GO:0002704 negative regulation of leukocyte mediated immunity GO:0002705 positive regulation of leukocyte mediated immunity GO:0002706 regulation of lymphocyte mediated immunity GO:0002707 negative regulation of lymphocyte mediated immunity GO:0002708 positive regulation of lymphocyte mediated immunity GO:0002709 regulation of T cell mediated immunity GO:0002711 positive regulation of T cell mediated immunity GO:0002715 regulation of natural killer cell mediated immunity GO:0002716 negative regulation of natural killer cell mediated immunity GO:0002717 positive regulation of natural killer cell mediated immunity GO:0002819 regulation of adaptive immune response GO:0002821 positive regulation of adaptive immune response GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002824 positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0006959 humoral immune response GO:0007159 leukocyte cell-cell adhesion GO:0009306 protein secretion GO:0019730 antimicrobial humoral response GO:0019731 antibacterial humoral response GO:0019882 antigen processing and presentation GO:0019883 antigen processing and presentation of endogenous antigen GO:0019884 antigen processing and presentation of exogenous antigen GO:0022407 regulation of cell-cell adhesion GO:0022409 positive regulation of cell-cell adhesion GO:0031341 regulation of cell killing GO:0031342 negative regulation of cell killing GO:0031343 positive regulation of cell killing GO:0031348 negative regulation of defense response GO:0031349 positive regulation of defense response GO:0032616 interleukin-13 production GO:0032633 interleukin-4 production GO:0032639 TRAIL production GO:0032640 tumor necrosis factor production GO:0032656 regulation of interleukin-13 production GO:0032673 regulation of interleukin-4 production GO:0032679 regulation of TRAIL production GO:0032680 regulation of tumor necrosis factor production GO:0032736 positive regulation of interleukin-13 production GO:0032753 positive regulation of interleukin-4 production GO:0032759 positive regulation of TRAIL production GO:0032760 positive regulation of tumor necrosis factor production GO:0032943 mononuclear cell proliferation GO:0032944 regulation of mononuclear cell proliferation GO:0032946 positive regulation of mononuclear cell proliferation GO:0034340 response to type I interferon GO:0034341 response to interferon-gamma GO:0035740 CD8-positive, alpha-beta T cell proliferation GO:0036037 CD8-positive, alpha-beta T cell activation GO:0042098 T cell proliferation GO:0042102 positive regulation of T cell proliferation GO:0042110 T cell activation GO:0042129 regulation of T cell proliferation GO:0042267 natural killer cell mediated cytotoxicity GO:0042269 regulation of natural killer cell mediated cytotoxicity GO:0042270 protection from natural killer cell mediated cytotoxicity GO:0042590 antigen processing and presentation of exogenous peptide antigen via MHC class I GO:0042742 defense response to bacterium GO:0045088 regulation of innate immune response GO:0045089 positive regulation of innate immune response GO:0045785 positive regulation of cell adhesion GO:0045824 negative regulation of innate immune response GO:0045953 negative regulation of natural killer cell mediated cytotoxicity GO:0046631 alpha-beta T cell activation GO:0046633 alpha-beta T cell proliferation GO:0046634 regulation of alpha-beta T cell activation GO:0046635 positive regulation of alpha-beta T cell activation GO:0046640 regulation of alpha-beta T cell proliferation GO:0046641 positive regulation of alpha-beta T cell proliferation GO:0046651 lymphocyte proliferation GO:0048002 antigen processing and presentation of peptide antigen GO:0048305 immunoglobulin secretion GO:0050670 regulation of lymphocyte proliferation GO:0050671 positive regulation of lymphocyte proliferation GO:0050708 regulation of protein secretion GO:0050714 positive regulation of protein secretion GO:0050777 negative regulation of immune response GO:0050830 defense response to Gram-positive bacterium GO:0050863 regulation of T cell activation GO:0050865 regulation of cell activation GO:0050867 positive regulation of cell activation GO:0050870 positive regulation of T cell activation GO:0051023 regulation of immunoglobulin secretion GO:0051024 positive regulation of immunoglobulin secretion GO:0051047 positive regulation of secretion GO:0051222 positive regulation of protein transport GO:0051249 regulation of lymphocyte activation GO:0051251 positive regulation of lymphocyte activation GO:0060333 interferon-gamma-mediated signaling pathway GO:0060337 type I interferon signaling pathway GO:0070486 leukocyte aggregation GO:0070489 T cell aggregation GO:0070661 leukocyte proliferation GO:0070663 regulation of leukocyte proliferation GO:0070665 positive regulation of leukocyte proliferation GO:0071346 cellular response to interferon-gamma GO:0071357 cellular response to type I interferon GO:0071593 lymphocyte aggregation GO:0071706 tumor necrosis factor superfamily cytokine production GO:0098542 defense response to other organism GO:1903037 regulation of leukocyte cell-cell adhesion GO:1903039 positive regulation of leukocyte cell-cell adhesion GO:1903532 positive regulation of secretion by cell GO:1903555 regulation of tumor necrosis factor superfamily cytokine production GO:1903557 positive regulation of tumor necrosis factor superfamily cytokine production GO:1904951 positive regulation of establishment of protein localization GO:2000564 regulation of CD8-positive, alpha-beta T cell proliferation GO:2000566 positive regulation of CD8-positive, alpha-beta T cell proliferation GO:2001185 regulation of CD8-positive, alpha-beta T cell activation GO:2001187 positive regulation of CD8-positive, alpha-beta T cell activation |
Molecular Function |
GO:0003823 antigen binding GO:0030881 beta-2-microglobulin binding GO:0033218 amide binding GO:0042277 peptide binding GO:0042287 MHC protein binding GO:0042288 MHC class I protein binding GO:0042605 peptide antigen binding GO:0046703 natural killer cell lectin-like receptor binding |
Cellular Component |
GO:0005769 early endosome GO:0010008 endosome membrane GO:0012507 ER to Golgi transport vesicle membrane GO:0030133 transport vesicle GO:0030134 ER to Golgi transport vesicle GO:0030135 coated vesicle GO:0030139 endocytic vesicle GO:0030176 integral component of endoplasmic reticulum membrane GO:0030658 transport vesicle membrane GO:0030659 cytoplasmic vesicle membrane GO:0030662 coated vesicle membrane GO:0030666 endocytic vesicle membrane GO:0030670 phagocytic vesicle membrane GO:0031227 intrinsic component of endoplasmic reticulum membrane GO:0031901 early endosome membrane GO:0032398 MHC class Ib protein complex GO:0042611 MHC protein complex GO:0042612 MHC class I protein complex GO:0044440 endosomal part GO:0045335 phagocytic vesicle GO:0071556 integral component of lumenal side of endoplasmic reticulum membrane GO:0098552 side of membrane GO:0098553 lumenal side of endoplasmic reticulum membrane |
KEGG |
hsa04144 Endocytosis hsa04145 Phagosome hsa04514 Cell adhesion molecules (CAMs) hsa04612 Antigen processing and presentation hsa04650 Natural killer cell mediated cytotoxicity |
Reactome |
R-HSA-1280218: Adaptive Immune System R-HSA-983170: Antigen Presentation R-HSA-1236975: Antigen processing-Cross presentation R-HSA-983169: Class I MHC mediated antigen processing & presentation R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-2172127: DAP12 interactions R-HSA-2424491: DAP12 signaling R-HSA-1236974: ER-Phagosome pathway R-HSA-1236977: Endosomal/Vacuolar pathway R-HSA-168256: Immune System R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell R-HSA-168249: Innate Immune System R-HSA-913531: Interferon Signaling R-HSA-909733: Interferon alpha/beta signaling R-HSA-877300: Interferon gamma signaling |
Summary | |
---|---|
Symbol | HLA-E |
Name | major histocompatibility complex, class I, E |
Aliases | EA1.2; EA2.1; HLA-6.2; MHC; QA1; HLA class I histocompatibility antigen, E alpha chain; MHC HLA-E alpha-1; M ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between HLA-E and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between HLA-E and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | HLA-E |
Name | major histocompatibility complex, class I, E |
Aliases | EA1.2; EA2.1; HLA-6.2; MHC; QA1; HLA class I histocompatibility antigen, E alpha chain; MHC HLA-E alpha-1; M ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of HLA-E in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | HLA-E |
Name | major histocompatibility complex, class I, E |
Aliases | EA1.2; EA2.1; HLA-6.2; MHC; QA1; HLA class I histocompatibility antigen, E alpha chain; MHC HLA-E alpha-1; M ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of HLA-E in various data sets.
|
Points in the above scatter plot represent the mutation difference of HLA-E in various data sets.
|
Summary | |
---|---|
Symbol | HLA-E |
Name | major histocompatibility complex, class I, E |
Aliases | EA1.2; EA2.1; HLA-6.2; MHC; QA1; HLA class I histocompatibility antigen, E alpha chain; MHC HLA-E alpha-1; M ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HLA-E. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | HLA-E |
Name | major histocompatibility complex, class I, E |
Aliases | EA1.2; EA2.1; HLA-6.2; MHC; QA1; HLA class I histocompatibility antigen, E alpha chain; MHC HLA-E alpha-1; M ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HLA-E. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HLA-E. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | HLA-E |
Name | major histocompatibility complex, class I, E |
Aliases | EA1.2; EA2.1; HLA-6.2; MHC; QA1; HLA class I histocompatibility antigen, E alpha chain; MHC HLA-E alpha-1; M ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HLA-E. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | HLA-E |
Name | major histocompatibility complex, class I, E |
Aliases | EA1.2; EA2.1; HLA-6.2; MHC; QA1; HLA class I histocompatibility antigen, E alpha chain; MHC HLA-E alpha-1; M ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of HLA-E expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | HLA-E |
Name | major histocompatibility complex, class I, E |
Aliases | EA1.2; EA2.1; HLA-6.2; MHC; QA1; HLA class I histocompatibility antigen, E alpha chain; MHC HLA-E alpha-1; M ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between HLA-E and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | HLA-E |
Name | major histocompatibility complex, class I, E |
Aliases | EA1.2; EA2.1; HLA-6.2; MHC; QA1; HLA class I histocompatibility antigen, E alpha chain; MHC HLA-E alpha-1; M ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting HLA-E collected from DrugBank database. |
There is no record. |